title: Administration of OKT3 as a two-hour infusion does not attenuate first-dose side effects.
authors.forename: R
authors.initials: R
authors.lastname: Kandaswamy
authors.forename: M
authors.initials: M
authors.lastname: Kamps
authors.forename: A J
authors.initials: AJ
authors.lastname: Matas
mesh_terms: D000328:Adult; D004334:Drug Administration Schedule; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D016853:Muromonab-CD3